Chondrosarcoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:03 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Chondrosarcoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of Regorafenib for Patients with Metastatic Bone Sarcomas https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-metastatic-bone-sarcomas/ Wed, 29 Apr 2026 15:00:51 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-regorafenib-for-patients-with-metastatic-bone-sarcomas/ This clinical trial is focused on studying the effects of a medication called regorafenib in patients with a type of cancer known as metastatic bone sarcoma. Metastatic bone sarcoma is a cancer that starts in the bones and can spread to other parts of the body. The purpose of the study is to evaluate how well regorafenib works in treating this condition and to assess its safety for patients.

Participants in the study will receive either regorafenib or a placebo, which is a substance with no active medication. The study will take place over several months, during which patients will be monitored regularly to see how their cancer responds to the treatment. This will involve various assessments, including imaging tests like MRI or CT scans, to track changes in the cancer. The study aims to determine if regorafenib can help control the cancer and improve the patients’ quality of life.

Throughout the study, patients will be closely observed for any side effects or changes in their condition. The information gathered will help researchers understand the potential benefits and risks of using regorafenib for treating metastatic bone sarcoma. This research is important for developing new treatment options for patients with this challenging type of cancer.

]]> Study on Trabectedin for Adults and Young Adults with Advanced Mesenchymal Chondrosarcoma https://clinicaltrials.eu/trial/study-on-trabectedin-for-adults-and-young-adults-with-advanced-mesenchymal-chondrosarcoma/ Wed, 29 Apr 2026 14:27:49 +0000 https://clinicaltrials.eu/trial/study-on-trabectedin-for-adults-and-young-adults-with-advanced-mesenchymal-chondrosarcoma/ This clinical trial is focused on studying a rare type of cancer called mesenchymal chondrosarcoma, which can occur in both bones and soft tissues. The study is specifically looking at cases that are positive for a genetic marker known as HEY1-NCOA2. The treatment being tested in this study is a medication called trabectedin, which is also known by the code name Ecteinascidin 743. Trabectedin is given as a solution through an intravenous infusion, meaning it is administered directly into the bloodstream through a vein.

The purpose of the study is to explore how effective trabectedin is in treating patients who have already received other types of chemotherapy, specifically those that include a group of drugs called anthracyclines. The study will involve patients who are 16 years or older and have advanced or spreading forms of mesenchymal chondrosarcoma. Participants will receive trabectedin and their response to the treatment will be monitored over time. The study aims to understand how well the tumors respond to the treatment and to gather information on the overall survival and progression-free survival of the patients.

Throughout the study, researchers will also look at the safety of trabectedin and explore the genetic and molecular characteristics of tumors that respond to the treatment compared to those that do not. This includes analyzing patterns in the tumor’s genetic material and evaluating the potential of using a technique called liquid biopsy, which involves testing blood samples to detect the presence of the HEY1-NCOA2 fusion, to predict how well a patient might respond to the treatment. The study is expected to continue until 2027, providing valuable insights into the treatment of this rare cancer type.

]]>